Mizuho cut shares of Achaogen (NASDAQ:AKAO) from a buy rating to a neutral rating in a report issued on Friday, MarketBeat Ratings reports.
Several other research firms have also issued reports on AKAO. Stifel Nicolaus lifted their price target on shares of Achaogen from $14.00 to $22.00 and gave the stock a buy rating in a research report on Tuesday, August 7th. BidaskClub lowered shares of Achaogen from a sell rating to a strong sell rating in a research report on Wednesday, July 18th. Zacks Investment Research upgraded shares of Achaogen from a hold rating to a buy rating and set a $4.75 price target on the stock in a research report on Wednesday, October 10th. Needham & Company LLC lowered shares of Achaogen from a buy rating to a hold rating in a research report on Tuesday, August 7th. Finally, SunTrust Banks decreased their price target on shares of Achaogen from $16.00 to $10.00 and set a buy rating on the stock in a research report on Monday, August 20th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $14.81.
Achaogen stock traded down $0.40 during mid-day trading on Friday, hitting $2.25. The company’s stock had a trading volume of 1,656,391 shares, compared to its average volume of 579,029. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.79 and a current ratio of 3.79. The firm has a market cap of $139.24 million, a price-to-earnings ratio of -0.71 and a beta of 0.67. Achaogen has a twelve month low of $2.10 and a twelve month high of $15.00.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Featured Article: What is a balanced fund?
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.